Grace Therapeutics, Inc. (GRCE) Financials

GRCE Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 66.7 million 2.8 million
Dec. 31, 2025 68.5 million 3.6 million
Sept. 30, 2025 66.6 million 3.8 million
June 30, 2025 69.8 million 6.3 million

GRCE Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -1.7 million -24000
Dec. 31, 2025 -2.2 million 314000
Sept. 30, 2025 -3.2 million 206000
June 30, 2025 -1.8 million 302000

GRCE Net Income

No data available :(

GRCE Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 17.0 million - -
Dec. 31, 2025 18.7 million - -
Sept. 30, 2025 16.9 million - -
June 30, 2025 20.0 million - -

GRCE Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 16.5 million
Dec. 31, 2025 16.9 million
Sept. 30, 2025 15.9 million
June 30, 2025 15.9 million

GRCE Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 420000 308589 -
Dec. 31, 2025 - 633924 2.7 million -
Sept. 30, 2025 - 792206 2.7 million -
June 30, 2025 - 955000 2.1 million -

GRCE Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 2000
Dec. 31, 2025 - 4116
Sept. 30, 2025 - 2000
June 30, 2025 - 2000

GRCE

Price: $2.33

52 week price:
1.79
5.18

Earnings Per Share: -0.47 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 40.2 million

Links: